Koers Celldex Therapeutics, Inc. Nasdaq
Aandelen
US15117B1035
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 3,39 mln. 3,18 mln. | Omzet 2025 * | 3,13 mln. 2,94 mln. | Marktkapitalisatie | 2,47 mld. 2,32 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -170 mln. -160 mln. | Nettowinst (verlies) 2025 * | -203 mln. -191 mln. | EV/omzet 2024 * | 644 x |
Nettoliquiditeiten 2024 * | 285 mln. 268 mln. | Nettoliquiditeiten 2025 * | 372 mln. 350 mln. | EV/omzet 2025 * | 669 x |
K/w-verhouding 2024 * |
-12,9
x | K/w-verhouding 2025 * |
-11,5
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,66% |
Recentste transcriptie over Celldex Therapeutics, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Tibor Keler
FOU | Founder | 65 | 01-01-83 |
Anthony Marucci
FOU | Founder | 62 | 01-01-83 |
Sam Martin
DFI | Director of Finance/CFO | 53 | 01-04-09 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Herbert Conrad
BRD | Director/Board Member | 91 | 01-03-08 |
Cheryl L. Cohen
BRD | Director/Board Member | 58 | 16-06-22 |
Harry H. Penner
BRD | Director/Board Member | 78 | 01-01-97 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,17% | 42,19 mld. | |
+10,92% | 42,24 mld. | |
+44,30% | 40,15 mld. | |
-6,20% | 28,31 mld. | |
+5,23% | 24,63 mld. | |
-24,79% | 18,2 mld. | |
+26,69% | 12,01 mld. | |
-3,13% | 11,76 mld. | |
+6,57% | 10,4 mld. |